Skip to main content

Prof. Dr. Dagmar Dilloo

Member

Department of Pediatric Haematology & Oncology

Medical Faculty, University of Bonn University Hospital of Bonn Adenauerallee 119 53113 Bonn

Website

Dagmar Dilloo

Recent publications

  • The PI3K inhibitor pictilisib and the multikinase inhibitors pazopanib and sorafenib have an impact on Rac1 level and migration of medulloblastoma in vitro.

    Journal of cellular and molecular medicine

    Authors: Leonie F Schoen, Rogerio B Craveiro, Torsten Pietsch, Thomas Moritz, Anja Troeger, Silvia Jordans, Dagmar Dilloo

  • Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first-line intensified treatment of pediatric patients with high-risk acute lymphoblastic leukemia in CoALL08-09 trial.

    Pediatric blood & cancer

    Authors: Kerstin Mezger, Sabine Ebert, Hannah Elisa Muhle, Udo Zur Stadt, Arndt Borkhardt, Dagmar Dilloo, Jörg Faber, Tobias Feuchtinger, Thomas Imschweiler, Norbert Jorch, Arnulf Pekrun, Irene Schmid, Franziska Schramm, Martin Zimmermann, Martin A Horstmann, Gabriele Escherich

  • Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative …

    Haematologica

    Authors: Gabriele Escherich, Udo Zur Stadt, Arndt Borkhardt, Dagmar Dilloo, Jörg Faber, Tobias Feuchtinger, Thomas Imschweiler, Norbert Jorch, Arnulf Pekrun, Irene Schmid, Franziska Schramm, Michael Spohn, Martin Zimmermann, Martin A Horstmann

All publications by Prof. Dr. Dagmar Dilloo